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Abstract 
Biomedical applications of carbon nanotubes have attracted much attention in recent years. 
Here, we summarize our previously developed protocols for functionalization and 
bioconjugation of single wall carbon nanotubes (SWNTs) for various biomedical applications 
including biological imaging, sensing and drug delivery. Sonication of SWNTs in solutions of 
phospholipid-polyethylene glycol (PL-PEG) is our most commonly used protocol of SWNT 
functionalization. Compared to other frequently used covalent strategies, our non-covalent 
functionalization protocol largely retains the intrinsic optical properties of SWNTs, which are 
useful in various biological imaging and sensing applications. Functionalized SWNTs are 
conjugated with targeting ligands for specific cell labeling in vitro or tumor targeting in vivo. 
Radio labels are introduced for tracking and imaging of SWNTs in real time in vivo. Moreover, 
SWNTs can be conjugated with small interfering RNA (siRNA) or loaded with chemotherapy 
drugs for drug delivery. These procedures take various times ranging from one to five days. 
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INTRODUCTION 
Carbon nanotubes with various unique physical and chemical properties have shown 
interesting applications in many fields including biomedicine.1, 2 Functionalized carbon 
nanotubes with water solubility and biocompatibility are able to cross cell membranes, shuttling 
a wide range of biologically active molecules including drugs, proteins, DNA and RNA, into 
cells.3-7 The cytotoxicity of carbon nanotubes is largely dependent on their surface 
functionalization, with minimal toxic effects for well functionalized, serum-stable nanotubes.1, 8 
We have shown that after intravenous injection into mice, well functionalized single-walled 
carbon nanotubes (SWNTs) are accumulated in reticuloendothelial systems (RES) are slowly 
excreted, mainly through the biliary pathway, without exhibiting obvious side effects to the 
treated mice9, 10. Recently, in vivo cancer treatment in an animal model has been realized by 
carbon nanotube-based drug delivery.11  
 
Carbon nanotubes are classified as single-walled carbon nanotubes (SWNTs) and 
multi-walled carbon nanotubes (MWNTs), depending on the number of graphene layers from 
which a nanotube is composed. SWNTs are quasi one dimensional quantum wires with sharp 
densities of electronic states (electronic DOS) at the van Hove singularities, and generally have 
more attractive unique intrinsic optical properties than MWNTS. SWNTs can be used as optical 
tags for biomedical detection and imaging.12-18 Ultra-sensitive ex vivo protein sensing with a 
detection limit as low as one femtomolar using SWNT Raman tags has been achieved utilizing 
the resonance Raman scattering property of SWNTs and surface enhanced Raman scattering 
(SERS).14 The Raman scattering, near-infrared (NIR) photoluminescence, and high optical 
absorbance of SWNTs have all been utilized for biomedical molecular imaging in vitro and in 
vivo.15-18 Thus, carbon nanotube bioconjugates are promising nanomaterials for biomedical 
applications. 
 
SWNTs may have various potential advantages over other nanomaterials in different areas of 
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nanobiotechnology. As an optical tag in biological imaging, SWNTs can be used in Raman, NIR 
fluorescence and photoacoustic imaging of cells and animals.12, 13, 15-18 Multimodality optical 
imaging could thus be achieved using SWNTs as the contrast agent. Quantum dots or surface 
enhanced Raman scattering gold / sliver nanoparticles normally only have a single imaging 
functionality.19, 20 In contrast to widely used fluorescent quantum dots, carbon nanotubes contain 
no heavy metals and thus have a safer chemical composition. In the area of drug delivery, 
SWNT-based siRNA delivery works for a large range of cells, including notoriously 
‘hard-to-transfect’ human T cells,4 which are inert to conventional liposomal transfection agents. 
SWNTs can be efficiently loaded with aromatic chemotherapy drugs such as doxorubicin via 
supramolecular π-π stacking,21 obtaining an ultra-high loading capacity superior to other drug 
carriers including liposomes and micelles. Moreover, the high optical absorbance of SWNTs can 
also be used in photothermal therapy,22, 23 which may potentially be combined with 
chemotherapy11, 21 and gene therapy,4, 24 both delivered by SWNTs to treat cancer in a more 
efficient manner. 
 
For biomedical applications, raw hydrophobic carbon nanotubes must be functionalized to 
afford water solubility and biocompatibility. Our previous studies have uncovered that the 
behaviors of carbon nanotubes in biological systems in vitro (such as cellular uptake) and in vivo 
(such as blood circulation time and biodistribution) are highly dependent on their surface 
chemistry.4, 9, 25 Developing proper surface functionalization on carbon nanotubes is thus the 
most critical step to produce nanotube bioconjugates for a desired application. There are two 
major types of functionalization protocols for carbon nanotubes, covalent reactions or 
non-covalent coating by amphiphilic molecules on nanotubes. Various covalent functionalization 
reactions, such as oxidation26, 27 of nanotubes and 1, 3-dipolar cylcoaddtion28 on the nanotube 
sidewalls, have been developed to produce water soluble nanotubes useful in certain biomedical 
applications such as drug delivery.2 Although covalent chemical reactions often allow stable 
functionalization on carbon nanotubes, the properties of SWNTs are degraded when the nanotube 
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side wall is damaged, dramatically decreasing the Raman scattering and NIR fluorescence 
signals of SWNTs.1 Therefore, covalently functionalized carbon nanotubes, have been widely 
used in drug and gene delivery,2, 29 but are usually not ideal for sensing and imaging 
applications.1 In contrast, the structure and optical properties of SWNTs are largely maintained 
when non-covalent functionalization is used. However, the stability and biocompatibility of 
many non-covalently functionalized SWNTs are not satisfactory. For example, SWNTs 
solubilized in small molecule surfactants (e.g., sodium dodecyl sulfate, SDS) will aggregate and 
precipitate if excess coating molecules are removed. An ideal functionalization should impart 
SWNTs with high water solubility, biocompatibility, minimal damage of nanotube structure, and 
functional groups available for further bioconjugation. 
Our group has developed systematic protocols for SWNT functionalization and 
bioconjugation in the past few years. Raw SWNTs are non-covalently functionalized by 
amphiphilic polymers, such as phospholipid-poly(ethylene glycol) (PL-PEG).6, 22 Functionalized 
SWNTs have excellent stability in the aqueous phase and are highly biocompatible. Targeting 
ligands including antibodies and peptides can be conjugated to SWNTs to recognize specific cell 
receptors, yielding targeted SWNT bioconjugates useful for biological sensing14 and 
imaging.15-18 We have also developed a protocol to label SWNTs with radioactive isotopes to 
track and image nanotubes in vivo by positron emission tomography (PET). In addition, 
SWNT-based siRNA transfection can be achieved by conjugating siRNA to SWNTs via a 
cleavable disulfide bond.4, 6 Furthermore, aromatic drug molecules can be non-covalently loaded 
on SWNTs by simple mixing for drug delivery.21 
Here, we systematically summarize the nanotube functionalization and bioconjugation 
protocols developed and used in our previous studies. Although our bioconjugation strategies 
apply for a wide range of biomolecules, only a few model systems are chosen to illustrate those 
protocols. Arg–Gly–Asp (RGD) peptide and Herceptin anti-Her2 antibody are used as targeting 
ligands. 64Cu is reported as an example of radiolabeling SWNTs. Anti-CXCR4 siRNA is chosen 
for siRNA conjugation and delivery. Finally, doxorubicin is demonstrated as an aromatic drug, 
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loaded onto SWNTs for drug delivery. These detailed protocols should be beneficial to scientists 
interested in further developing biological applications of novel nanomaterials. 
 
Experimental design 
Non-covalent Functionalization of SWNTs by PL-PEG 
SWNTs are non-covalently functionalized by sonication of raw, hydrophobic nanotubes in 
water solutions of amphiphilic polymers (e.g., PL-PEG).6, 22 The hydrophobic lipid chains of 
PL-PEG are strongly anchored onto the nanotube surface while the hydrophilic PEG chain 
affords SWNT water solubility and biocompatibility. After removal of excess PL-PEG molecules, 
functionalized SWNTs exhibit excellent stability in various aqueous phases including water, 
physiological buffers (e.g., phosphate buffered saline, PBS), cell medium and whole serum. The 
concentration of a SWNT solution can be determined by its optical density at 808 nm measured 
by a UV-VIS-NIR spectrometer with a weight extinction coefficient of 0.0465 mg L-1 cm-1 
(dividing the optical density at 808 nm by the extinction coefficient gives the concentration) 22 
The length distribution of functionalized SWNTs can be determined by an atomic force 
microscope (AFM). Those non-covalently functionalized SWNTs retain their Raman and NIR 
fluorescence properties and are useful in biological detection and imaging applications. The 
functional group (e.g., amine) on the PEG terminal is available for further bioconjugation (Fig. 
1).  
 
Conjugation with Targeting Ligands 
Targeting ligands including antibodies and peptides can be conjugated to SWNTs to 
recognize specific cell receptors (Fig., 2). Herceptin is a monoclonal antibody that binds 
specifically to the Her2/neu receptor over-expressed on a wide range of human breast cancer 
cells.30 The RGD peptide targets integrin αvβ3 receptors that are up-regulated on fast-growing 
tumor vasculature cells and many types of cancer cells.31 The antibody Herceptin is first thiolated 
by Traut’s reagent following standard protocols15, 16 and used immediately after purification. The 
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Traut’s reagent reacts with amino groups on the antibody and produces active thiol groups useful 
for bioconjugation. Thiolated RGD peptide synthesized following a previously published 
protocol 32 is used directly. The thiolated antibody or peptide should be protected from oxidation 
by adding Ethylenediaminetetraacetic acid (EDTA) to prevent heavy metal catalyzed oxidization, 
or Tris- (2-carboxyethyl)phosphine hydrochloride (TCEP) as a reducing agent, during the 
conjugation with nanotubes. Maleimide groups are introduced onto SWNTs by reacting 
PL-PEG-amine functionalized SWNTs with a sulfosuccinimidyl 4-N-maleimidomethyl 
cyclohexane-1-carboxylate (Sulfo-SMCC) bifunctional linker. The activated SWNTs are then 
reacted with thiolated antibodies or peptides, obtaining targeted SWNT bioconjugates, which can 
be used in multiplexed Raman spectroscopic imaging,15, 18 ultra-sensitive Raman detection of 
proteins,14 NIR fluorescence imaging, 16 photoacoustic imaging,17 and targeted photothermal 
therapy.22, 23 The targeting ability of SWNT bioconjugates (e.g., SWNT-RGD) can be 
characterized by in vitro Raman spectroscopic imaging experiments, to examine the staining of 
integrin αvβ3 positive U87MG cells and αvβ3 negative MCF-7 cells incubated with the 
SWNT-RGD conjugate . 
 
Radiolabeling of SWNTs 
 To image and track SWNTs in vivo by positron emission tomography (PET), SWNTs are 
labeled with a radioactive isotope (Fig. 3).25 PET imaging provides three dimensional 
distribution information of radio labeled nanotubes in live mice at the real time. To obtain RGD 
conjugated radiolabeled SWNTs, SWNTs are first reacted with a mixture of sulfo-SMCC and 
N-Hydroxysuccinimide (NHS) activated 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (DOTA), and then conjugated to RGD-SH. After removal of excess reagents, 64Cu 
radioactive isotope can then be complexed to the DOTA rings on the SWNTs to achieve 
radiolabeling. The radiolabeled, targeted SWNT bioconjugate can be used for in vivo PET 
imaging of mice bearing integrin αvβ3 positive e.g., U87MG human glioblastomas tumors.25 5-10 
million of U87MG cells should be injected subcutaneously on the shoulder of a nude mouse. The 
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mice can be used 2-3 weeks after tumor inoculation. PET imaging should be carried out at 0.5 h, 
2 h, 4 h, 6 h and 24 h post injection (p.i.). Mice may be sacrificed at 24 h p.i. when the blood 
circulation of nanotubes is ended.  
 
SiRNA Conjugation to SWNTs via Cleavable Disulfide Bond 
 The intracellular molecular delivery ability of SWNTs can be used for siRNA transfection.4, 6 
In this example we chose to use CXCR4, a chemokine receptor that plays an important role in 
the entry of HIV virus into human T cells.33 SWNTs are first reacted with a bifunctional linker, 
N -Succinimidyl 3-(2-pyridyldithio)-propionate (Sulfo-LC-SPDP), and then conjugated with 
thiolated siRNA via a cleavable disulfide bond (Fig. 4). Two CXCR4 siRNA with different 
sequences and a control luciferase siRNA are used. Dithiothreitol (DTT) is used to cleave any 
disulfide bond formed during storage of thiolated siRNA and removed by a NAP-5 column prior 
to the conjugation of siRNA with SWNTs. The SWNT-siRNA conjugates should be sterilized by 
centrifugation before cell incubation. Once transported into cells via endocytosis, siRNA is 
released from SWNTs by sulfide cleavage and then binds to CXCR4 mRNA to induce gene 
silencing. CXCR4 receptor expression on CEM.NKR cells, a human T cell line inert to 
commercial cationic liposome transfection agents,34 is knocked-down after cells are incubated 
with the SWNT-siRNAanti-CXCR4 conjugate for 3 days. The CXCR4 expression levels of cells can 
be determined by labeling cells with PE-anti-CXCR4 antibody and flow cytometry (FACS) 
measurement with dead cells excluded by propidium iodide (PI) staining. Control experiments 
using commercial cationic liposome based transfection agents to transfect CEM.NKR with 
CXCR4 siRNA showed no obvious gene silencing effect. Mis-matched siRNA sequence 
(luciferase siRNA) also did not affect CXCR4 expression. 
 
Doxorubicin Loading on Functionalized SWNTs 
 SWNTs, with all atoms exposed on their surface, have ultra-high surface area available for 
binding of aromatic molecules via supramolecular π-π stacking.21 Functionalized SWNTs with or 
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without targeting ligands can be loaded with doxorubicin (DOX), an aromatic chemotherapy 
drug used for various types of cancers, by simply mixing of the two solutions at a slightly basic 
pH. Excess un-loaded DOX can be removed by filtration. The optical absorption of SWNT-DOX 
at 490 nm after subtraction of the SWNT absorption (at the same nanotube concentration) can be 
used to calculate the DOX concentration and loading in the SWNT-DOX complex.21 Based on 
the UV-VIS-NIR absorption spectra, up to 4 grams of DOX can be loaded on 1 gram of SWNTs. 
The toxicity of SWNT-DOX is lower than that of free DOX, but can be enhanced when 
conjugated with a targeting ligand such as RGD peptide, for targeted drug delivery. Toxicity 
assays are based on triplicate sample and can be carried out by testing cell viabilities after 
incubating cells with free DOX, SWNT-DOX and SWNT-RGD-DOX at series of DOX 
concentrations using a CellTiter 96 kit (Promega). The cell viability of the untreated control is 
defined as 100%. 
 
 
MATERIALS 
Reagents 
? Hipco single walled carbon nanotubes (Unidym Inc)  
! CAUTION  Hipco SWNTs are very light and could become airborne. Inhalation of SWNTs 
should be avoided. Wear goggles, lab coat and face-mask during experiments.  
? Isopotically Modified pure C12, pure C13 and mixed C12/C13 SWNTs, (Tsinghua-Foxconn 
Nanotechnology Research Center, China; see Reagent Setup) 
? PL-PEG5000-Amine (NOF cooperation, cat. no. DSPE-050PA) 
? PL-PEG2000-Amine (NOF cooperation, cat. no. DSPE-020PA) 
? RGD peptide (c(RGDyK); Peptides International) 
? Thiolated RGD peptide (see Reagent Setup) 
? Herceptin (Genetech Inc) 
? Sulfo-SMCC (Sulfosuccinimidyl 4-N-maleimidomethyl cyclohexane-1-carboxylate) (Pierce, 
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cat. no. 22322) 
? Sulfo-NHS (N-hydroxysulfosuccinimide) (Pierce, cat. no. 24510) 
? Sulfo-LC-SPDP (N -Succinimidyl 3-(2-pyridyldithio)-propionate) (Pierce, cat. no. 21650) 
? Traut’s Reagent (2-Iminothiolane•HCl) (Pierce, cat. no. 26101) 
? EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) (Pierce, cat. no. 
22981) 
? DOTA (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid) (Sigma-Aldrich, cat. no. 
86734) 
? DTT (DL-Dithiothreitol) (Sigma-Aldrich, cat. no. 43815) 
? Sodium Bicarbonate (Sigma-Aldrich, cat. no. S6297) 
? Sodium Hydroxide (Sigma-Aldrich, cat. no. 221465) 
! CAUTION  Sodium Hydroxide is a corrosive strong base. Wear goggles, lab coat and 
face-mask during experiments. 
? DMSO (Dimethyl sulfoxide), 99.9%, anhydrous (Sigma-Aldrich, cat. no. 276855) 
? EDTA (Ethylenediaminetetraacetic acid) solution (Sigma-Aldrich, cat. no. 03690) 
? TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Sigma-Aldrich, cat. no. C4706) 
? Sodium Acetate (Sigma-Aldrich, cat. no. S8750) 
? Acetic Acid (Sigma-Aldrich, cat. no. 242853) 
! CAUTION  Acetic Acid is evaporative and corrosive. Wear goggles, lab coat and face-mask 
during experiments. Handle acetic acid inside a hood. 
? Chelex 100 sodium form (Sigma-Alrich, cat. no. C7901) 
? DOX (Doxorubicin HCl, Tecoland) 
? U87MG human glioblastoma cells (ATCC, cat. no. HTB-14; see Reagent Setup) 
? MCF-7 human breast cancer cells (ATCC, cat. no. HTB-22; see Reagent Setup) 
? BT-474 human breast cancer cells (ATCC, cat. no. HTB-20; see Reagent Setup) 
? CEM.NKR human T-lymphoblastoid cells (NIH Aids Reagents Program, cat. no. 795081; see 
Reagent Setup) 
 10
? Low-glucose DMEM Medium (Invitrogen, cat. no. 11885-084) 
? High-glucose DMEM Medium (Invitrogen, cat. no. 21063-045) 
? RMPI-1640 Medium (Invitrogen, cat. no. 11875-093) 
? Fetal bovine serum (FBS) (Invitrogen, cat. no. 10437-028) 
? Phosphate buffered saline (PBS), 10×, pH 7.4 (Invitrogen, cat. no. 70011-069)  
? Phosphate buffered saline (PBS), 1×, pH 7.4 (Invitrogen, cat. no. 10010-049)  
? Penicillin-Streptomycin, liquid (10,000 units penicillin;10,000 µg streptomycin) (Invitrogen 
cat. no. 15140-163) 
? CXCR4 siRNA: sequence-a: 5'-Thiol-GCG GCA GCA GGU AGC AAA GdTdT-3’; 
sequence-b: 5'-Thiol-AUG GAG GGG AUC AGU AUA UdTdT. (Dharmacon RNAi 
Technology) 
? Luciferase siRNA (control): 5’-Thiol-CUU ACG CUG AGU ACU UCG AdTdT-3’. 
(Dharmacon RNAi Technology) 
? PE-anti-CXCR4 antibody, (Caltag Laboratories, cat. no. MHCXCR404) 
? Propidium iodide (PI) solution, 1.0 mg/ml in water (Sigma-Aldrich, cat. no. P4864) 
! CAUTION  Propidium iodide causes eye, skin and respiratory irritation and is harmful if 
swallowed. Wear goggles, lab coat and face-mask during experiments. 
? Lipofectamine2000 (Invitrogen, cat. no. 11668019) 
? LipofectamineRNAiMAX (Invitrogen, cat. no. 13778075) 
? siPORT (Ambion, cat. no. AM4510) 
? HiPerFect (Qiagen, cat. no. 301704 ) 
? CellTiter 96 MTS assay kit (Promega, cat. no. G3580) 
? Isoflurane (RxElite Inc., cat. no. NDC60307-120-25) 
! CAUTION Isoflurane is a profound respiratory depressant. Wear goggles, lab coat and 
face-mask during experiments. Handle isoflurane inside a hood when appropriate. Closely seal 
the bottle after use. 
? 64CuCl2 radioactive isotope (University of Wisconsin-Madison) 
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! CAUTION Please obtain appropriate training for handling radioactive materials. Wear goggles, 
lab coat, mask, radiation dosimeter badge and rings during experiment. Handling of radioactive 
isotopes should only be performed in designated rooms for those experiments. Check any 
possible radioactive contamination after experiments.  
? U87MG tumor-bearing athymic nude mice (Harlan; see Reagent Setup) 
! CAUTION Please obtain appropriate training from the institution regarding animal handling. 
Animal protocols must be in place before performing animal studies. 
 
Equipment 
? Bath Sonicator (Cole-Parmer, cat. no. 08849-00) 
? Accu Spin 400 centrifuge (Fisher Scientific, cat. no. 75005194) 
? Sorvall Legend Mach 1.6R centrifuge (Kendro Laboratory Products, cat. no. 75004337) 
? Amicon centrifugal filter device 4ML, 10,000 MWCO (Millipore, cat. no. UFC801024) 
? Amicon centrifugal filter device 4ML, 100,000 MWCO (Millipore, cat. no. UFC810024) 
? Microcon Ultracel YM-100 filter device 0.5ML, 100,000 MWCO (Millipore, cat. no. 42412) 
? Illustra NAP-5 columns, Sephadex G-25 DNA Grade (GE Healthcare, cat. no. 17-0853-01) 
? Flow cytometer (FACScan, Becton Dickinson)  
? Cary-6000i UV-VIS-NIR Spectrometer (Varian Inc) 
? Tecan Spectrafluor Plus microplate reader (Tecan Group Ltd) 
? Confocal Raman microscope (Horiba-Jobin-Yvon Inc) 
? Micro-PET R4 rodent model scanner (Concorde Microsystems) 
 
Reagent Setup 
Isotopically Modified SWNTs  13C-doped SWNTs are produced by Profs. Kaili Jiang and 
Shoushan Fan at Tsinghua-Foxconn Nanotechnology Research Center, Department of Physics, 
Tsinghua University, China. The detailed method has been reported earlier.15 
Thiolated RGD (RGD-SH) Peptide  Thiolated RGD (RGD-SH) peptide is prepared following 
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a previously reported protocol.32 
10 mM RGD-SH solution  Dissolve 1.2 mg of RGD-SH in 200 μl water (~10 mM). Store 
RGD-SH solution at -20 oC in small aliquots to avoid too many freeze-thaw cycles. The solution 
can be stable for up to 6 months if used and stored properly.  
100 μM SiRNA solution  Dissolve siRNA purchased from Dharmacon in the desired amount of 
RNAse free water to reach a siRNA concentration of 100 μM. Store siRNA solution at -20 oC in 
small aliquots to avoid too many freeze-thaw cycles. The solution can be stable for up to 6 
months if used and stored properly. 
0.5 M Sodium Bicarbonate (NaHCO3) Buffer  Dissolve 8.4 g sodium bicarbonate in 200 ml 
water. The solution can be stored at room temperature in a plastic bottle and stable for 6 months. 
0.1 M Sodium Hydroxide (NaOH) Solution  Dissolve 1.0 g sodium hydroxide in 250 ml 
water. The solution can be stored at room temperature in a plastic bottle and stable for 6 months. 
0.1 M Sodium Acetate Buffer (NaAcO, pH6.5)  Dissolve 1.64 g sodium acetate in 200 ml 
water. Add 22 mg acetic acid liquid. Add 1 g of Chelex 100 beads into the buffer to avoid heavy 
metal ion contamination.  
Cell Culture  Culture U87MG cells in DMEM (low glucose) supplemented with 10% (vol/vol) 
FBS and 1% (vol/vol) Penicillin-Streptomycin at 37 oC. Culture MCF-7 cells in DMEM (high 
glucose) supplemented with 10% (vol/vol) FBS and 1% (vol/vol) Penicillin-Streptomycin at 37 
oC. Culture BT474 cells in DMEM (high glucose) supplemented with 5 g L-1 glucose, 10% 
(vol/vol) FBS and 1% (vol/vol) Penicillin-Streptomycin at 37 oC. Culture CEM.NKR cells in 
RPMI-1640 supplemented with 10% (vol/vol) FBS at 37 oC. All cells are cultured in 5% CO2 
atmosphere.  
U87MG tumor model  Inject 5 × 106 U87MG cells subcutaneously into athymic nude mice (on 
their shoulders). Wait for 3-4 weeks before imaging, until tumor sizes reach 300~500 mm3.  
! CAUTION Please obtain appropriate training from the institution regarding animal handling 
and have animal protocols in place before performing animal studies. 
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Equipment Setup 
Raman Microscope  Confocal Raman spectroscopic imaging is carried out using a 
Horiba-Jobin-Yvon Raman confocal microscope with a 785 nm laser (80mW) as the excitation 
light source. A 50× objective was used for imaging with ~1 μm laser spot size. A 1 mm pin-pole 
was applied to restrict the spatial resolution in z-axis to be ~1 μm. Each Raman spectroscopic 
map contains at least 100 × 100 spectra with a 0.5 s integration time for each spectrum. 
FACS machine   FACS measurement is performed using a Becton Dickinson FACScan. A 
488nm laser is used as the excitation light source. Channel one, two and three collect green, 
yellow and red fluorescence, respectively. A flow rate of 200~400 cells / second is used in the 
measurement. 
 
 
PROCEDURE 
Functionalization of SWNTs 
1|  Weigh 1mg of Hipco SWNTs (or isotopically modified SWNTs) and 5 mg of 
PL-PEG5000-Amine or PL-PEG2000-Amine into a 20 ml glass scintillation vial. Add 5 ml of 
water. Dissolve DSPE-PEG completely by shaking. 
! CAUTION  Hipco SWNTs are very light and could become airborne. Inhalation of SWNTs 
should be avoided. Wear goggles, lab coat and face-mask during experiments.  
 
2|  Sonicate the above vial in a bath sonicator for 60 min at room temperature. Change the water 
in the water bath every 20 min to avoid over heating. 
 
▲ CRITICAL STEP  Make sure the vial is at the best position in the bath sonicator to ensure 
the most efficient sonication.? TROUBLESHOOTING 
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3|  Centrifuge the above SWNT suspension for 6 h, at 24,000 xg, room temperature (~22 oC). 
Collect the supernatant solution.  
 
4|  Record the UV-VIS-NIR absorption spectrum of the obtained SWNT solution. The final 
SWNT concentration normally ranges from 40 mg L-1 to 70 mg L-1  .Store the SWNT solution 
at 4 oC. 
■ PAUSE POINT  The PL-PEG functionalized SWNT solution can be stored at 4 oC for 1-2 
months before bioconjugation. It is highly recommended to store SWNT solutions in the 
presence of excess PL-PEG (before removal of excess PL-PEG in Step 5). 
 
5|  Add 1 ml of SWNT solution from the stock prepared in Step 3 into a 4 ml Amicon 
centrifugal filter device with a molecular weight cut off (MWCO) of 100 kDa. Add 3 ml of water  
and centrifuge the device for 10 min, at 4,000 xg, room temperature. The leftover volume in the 
filter should be less than 0.5 ml. Fill the filter device with water to 4 ml. Wash 5-6 times by 
repeating the centrifuge / water adding steps, to completely remove excess PL-PEG in the SWNT 
solution. Adjust the final SWNT solution to a concentration of ~50 mg L-1 by adding the required 
amount of water. The concentration of SWNT solution is measured by UV-VIS-NIR 
spectrometer with a weight extinction coefficient of 0.0465 mg L-1 cm-1 at 808 nm. 
? TROUBLESHOOTING 
 
6|  SWNT can be functionalized with Option A Targetting antibodies, Option B radiolabeling, 
Option C siRNA, Option D with doxorubicin. 
 
Option A. Conjugation with RGD peptide 
i)  Dissolve 0.5 mg of Sulfo-SMCC in 50 μl of DMSO. Add 0.5 ml of 50 mg L-1 SWNT 
functionalized by PL-PEG5000-Amine solution from Step 5. Add 60 μl of PBS (10×). React at 
room temperature for 2 h. 
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ii)  Remove excess Sulfo-SMCC by an Amicon centrifugal filter device (MWCO = 100kDa). 
Wash 5-6 times. Add water to a volume of 0.5 ml.  
 
▲ CRITICAL STEP The final SWNT solution should be immediately mixed with thiolated 
RGD. 
 
iii)  Dissolve ~2 mg of TCEP in 20~25 μl of 0.5 M sodium bicarbonate. Add sodium 
bicarbonate buffer slowly until the solution reaches pH 6. The pH is measured by a pH test paper. 
Add required volume (calculated by the exact weight of TCEP and the exact volume of sodium 
bicarbonate buffer added) of water so that the final TCEP concentration is 0.2 M.  
! CAUTION  Always prepare the TCEP solution immediately before use. TCEP-HCl solution 
in water has a very acidic pH. 
 
iv)  Mix 0.5 ml Sulfo-SMCC activated SWNT solution from Step ii with 50 μl of 10×PBS, 10 
μl of 100 μM RGD-SH solution and 25 μl of the TCEP solution from Step iii. The final reaction 
solution should have a SWNT concentration of ~40 mg L-1, RGD-SH concentration of ~0.2 mM 
and TCEP concentration of ~10 mM. These concentrations are based on the volumes and initial 
concentrations of various solutions added into the reaction mixture. Allow the reaction to 
proceed for 24 h at 4 oC. 
 
v)  Remove excess RGD and TCEP in the above solution using an Amicon centrifugal filter 
device (MWCO = 100 kDa). Wash 5-6 times as described in Step 5. Store the SWNT-RGD 
conjugate at ~50 mg L50 mg L-1 in water at 4 oC. 
■ PAUSE POINT  The SWNT-RGD conjugate can be stored at 4 oC for 2-3 weeks without 
losing targeting activity.  
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vi)  Cell staining  
a) Collect U87MG cells and MCF-7 cells by trypsinization in cell plates and gentle 
centrifugation for 7 min in 1.5 ml centrifuge tubes, at 300g, room temperature. 
Re-suspend the pellet in RMPI-1640 cell medium with 10% (vol/vol) FBS. Count the 
numbers of cells to make sure a density of ~1 million cells ml-1.. 
b) Add 50 μl of SWNT-RGD from Step v into 200 μl of U87MG cells (positive) and 200 
μl of MCF-7 cells (negative). Incubate for 1 h at 4 oC.. 
c) Wash the above cells with 200 μl of 1x PBS 3 times after incubation. The cells may be 
stored in 1x PBS at 4 oC for a few hours before Raman imaging without changing 
Raman imaging results. 
 
vii) Raman Imaging 
a) Seal a drop of cell suspension between two thin plastic cover-slips. 
b) Carry out Raman spectroscopic imaging of the labeled SWNTs using a 
Horiba-Jobin-Yvon Raman confocal microscope.15 
 
Option B. Conjugation with Targeting Antibodies 
i)  Dissolve 0.5 mg of Sulfo-SMCC in 50 μl of DMSO. Add 0.5 ml of SWNT functionalized by 
PL-PEG5000-Amine solution from Step 5. Add 60 μl of PBS (10×). React at room temperature 
for 2 h. 
 
ii)  Remove excess Sulfo-SMCC using an Amicon centrifugal filter device (MWCO = 100kDa). 
Wash 5-6 times as described in Step 5. Add water to a final volume of 0.5 ml.  
 
▲ CRITICAL STEP The final SWNT solution should be immediately mixed with thiolated 
Herceptin. 
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iii)  Immediately after the Sulfo-SMCC reaction with SWNTs is started (Option B (ii)), weigh 
1~2 mg of Traut’s reagent into a 2 ml plastic tube. Based on the weight, add the desired volume 
of water so that the final concentration of Traut’s reagent is 5 mM. Mix 6 μl of 140 μM 
Herceptin into a 0.5 ml plastic tube with 10 μl of 1×PBS, 1.7 μl of Traut’s reagent solution, and 1 
μl of 0.5 M EDTA solution. The molar ratio of Traut’s reagent:antibody is about 10:1. Incubate 
the reaction solution for 1.5-2 h at 4 oC.  
 
iv)  Add 300 μl of 1× PBS into the solution prepared in Step iii, remove the excess Traut’s 
reagent by filtration with a Microcon Ultracel YM-100 filter device. Centrifuge for 6~8 min at 
10,000 xg, room temperature  until the leftover volume is less than 10 μl.  
 
CRITICAL STEP Use the thiolated Herceptin immediately. 
 
v)  Mix the thiolated Herceptin from Step iv with 0.5 ml of Sulfo-SMCC modified SWNTs 
from Step ii. Add 50 μl of 10× PBS and 2 μl of 0.5 M EDTA. Incubate the reaction solution for 
24 h at 4 oC. The conjugate can be used directly without further purification.  
■ PAUSE POINT  The SWNT-Herceptin conjugate can be stored at 4 oC for 2-3 weeks without 
losing targeting activity. 
 
Option C. Radiolabeling of SWNTs  
i)  Dissolve 2 mg of DOTA in 50 μl of 0.1 M sodium hydroxide solution. Dissolve 2 mg of 
Sulfo-NHS and 1.5 mg of EDC in 50 μl of water. Add 30 μl of the Sulfo-NHS/EDC solution to 
the 50 μl DOTA solution. Incubate for 15 min at room temperature. Check the solution pH using 
pH test paper. The pH in the incubation solution should be pH 5-6. Slowly add more 0.1M 
sodium hydroxide solution if the pH is below 5. Molar ratio: DOTA : EDC: Sulfo-NHS ~ 1 : 1 : 
1.2. 
▲ CRITICAL STEP  Use EDC and Sulfo-NHS immediately after they are dissolved in water.  
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ii)  Dissolve 0.5 mg of Sulfo-SMCC in 20 μl of DMSO and mix with 10 μl of the 
DOTA:EDC:Sulfo-NHS solution from Step i. Add 500 μl of PL-PEG5000-Amine functionalized 
SWNT solution from Step 5. Add 60 μl of 10x PBS. Incubate the reaction solution for 2 h at 
room temperature. 
 
iii)  Remove excess Sulfo-SMCC, DOTA, EDC and Sulfo-NHS using an Amicon centrifugal 
filter device (MWCO = 100 kDa). Wash 5-6 times as described in Step 5. Add water to a final 
volume of 0.5 ml. 
 
iv)  Mix 0.5 ml of the SWNT solution from Step iii with 50 μl of 10×PBS, 10 μl of 100 μM 
RGD-SH solution, and 10 μl of 0.2 mM TCEP solution prepared in Option A, step iii. The final 
reaction solution has a SWNT concentration of ~40 mg L-1, RGD-SH concentration of ~0.2 mM 
and TCEP concentration of ~10 mM. Let the reaction proceed for 24 h at 4 oC. 
 
v)  Remove excess RGD and TCEP in the above solution using an Amicon centrifugal filter 
device (MWCO = 100 kDa). Wash 5-6 times as described in Step 5. Measure the concentration 
of final SWNT-RGD solution by UV-VIS-NIR spectroscopy. Store the SWNT-RGD conjugate at 
~50 mg L-1 in water at 4 oC.  
■ PAUSE POINT  The SWNT-RGD conjugate can be stored at 4 oC for 2-3 weeks without 
losing targeting activity.  
 
vi)  Dilute 10~20 mCi of 64CuCl2 in 0.5 ml of 0.1 M sodium acetate buffer (pH 6.5). Add a 
fraction of this solution (2 mCi activity) to 100 μl of RGD/DOTA co-conjugated SWNT solution 
prepared in Step v. Add 300 μl of 0.1 M sodium acetate buffer (pH 6.5). Incubate the reaction 
mixture for 1 h at 40 °C with constant shaking.  
! CAUTION  Please obtain appropriate training for handling radioactive materials. Wear 
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goggles, lab coat, mask, radiation dosimeter badge and rings during experiment. Handling of 
radioactive isotopes should only be performed in designated rooms for those experiments. Check 
any possible radioactive contamination after experiments.  
 
vii) Remove excess 64Cu by filtration with a Microcon Ultracel YM-100 filter device. Centrifuge 
for 6~8 min at 10,000 g until the leftover volume is less than 10 μl. Wash 3~4 times by adding 
200-300 μl water and centrifuge for 6~8 min at 10,000 g each time. Re-suspend the final labeled 
SWNTs in 500 μl of 1X PBS (SWNT concentration ~10 mg L-1). Radio labeling yield is 
determined by γ-counting. 
! CAUTION  Radio isotope wastes including contaminated devices such as filters should be 
collected and disposed in designated containers shielded with lead.   
? TROUBLESHOOTING 
 
viii) Inject 150 μl of ~10 mg L-1 radio labeled SWNTs (Step vii) into U87MG tumor bearing 
mice via the tail vein. 
! CAUTION Please obtain appropriate training from the institution regarding animal handling. 
Animal protocols must be in place before performing animal studies. 
 
viii) Image the mice under a micro-PET scanner at different time points post injection e.g., 0.5 h, 
2 h, 4 h, 6 h, 24 h. Process PET data according to a previously established protocol.25  
 
 
ix) Scarifice mice 24 h post injection.  
 
! CAUTION  The animal bodies should be collected in a designated freezer for radioactive 
contaminated biohazardous waste. Label all animal cages clearly with radioactive marks. Leave 
contaminated cages in the radioactive work designated animal room for a week until a complete 
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decay of 64Cu (half-life ~ 12.7h) before cleaning. Check any possible radioactive contamination 
after experiments. 
 
 
Option D. SiRNA Conjugation to SWNTs via Cleavable Disulfide Bond 
i)  Mix 500 μl of PL-PEG2000-amine functionalized SWNTs from Step 5 with 0.5 mg of 
Sulfo-LC-SPDP. Add 50 μl of 10X PBS. Incubate for 2 h at room temperature. 
 
ii)  Immediately after Step i is initiated, prepare 10 mM of DTT solution by dissolving 1.54 mg 
of DTT in 1 ml of water. Mix 15 μl of 100 μM siRNA (siRNACXCR4 or siRNAluc) with 1.5 μl of 
DTT solution. Allow the reaction to proceed for 1.5 h at room temperature.  
 
iii) After Step i, remove the excess Sulfo-LC-SPDP from the SWNT solution using an Amicon 
centrifugal filter device (MWCO = 100 kDa). Wash 5-6 times by adding 3-4 ml DNAse / RNAse 
free water and centrifuge for 6~8 min at 10,000 g each time. Keep the final volume to less than 
10 μl.  
 
CRITICAL STEP The obtained activated SWNTs should be used immediately for siRNA 
conjugation. 
 
iv)  After Step ii, in parallel with Step iii, purify DTT treated with the siRNA using a NAP-5 
column following the manufacturer’s protocol. Elute the siRNA from the column with DNAse / 
RNAse free 1X PBS.  
 
v)  Re-suspend the activated SWNTs from Step iii with the 500 μl of purified siRNA solution 
from Step iv. Allow the conjugation to proceed for 24 h at 4 oC. The final SWNT and siRNA 
concentrations are ~40 mg L-1 and ~2.5 μM, respectively. 
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▲ CRITICAL STEP  Use the SWNT-siRNA conjugate immediately after synthesis. This will 
reduce the chance of bacteria contamination and siRNA degradation. 
 
vi)  For the siRNA transfection, plate CEM.NKR cells in a 24-well plate with 500 μl of cells per 
well. The cell density should be ~1 × 105 cells ml-1. 
 
vii) To remove aggregates, centrifuge the SWNT-siRNA solutions prepared in Step v for 10 min, 
at 10,000 xg, 4 oC. Add 100 μl of the SWNT-siRNACXCR4 or SWNT-siRNAluc conjugate to each 
well. The final SWNT and siRNA concentrations are ~10 mg L-1 and ~500 nM, respectively, in 
the cell medium. 
 
viii) Transfect CEM.NKR cells with 500 nM siRNACXCR4 using commercial transfection agents, 
(e.g.,) Lipofectamine2000 (Invitrogen), LipofectamineRNAiMAX (Invitrogen), siPORT 
(Ambion) and HiPerFect (Qiagen) following the manufacturers’ protocols.  
 
ix) Incubate the cells at 37 oC, 5% CO2 for 3 d before analysis. 
TROUBLESHOOTING 
 
x) To analyze the effect of the RNAi, wash each well of cells (non-adherent) with 200 μl 1X PBS 
twice by centrifuge for 7 minutes, at 300 g, room temperature. Re-suspend the cells in 200 μl of 
1X PBS. Add in 2 μl of PE-anti-CXCR4 antibody solution. Incubate at for 1 h at 4 oC.  
 
xi) Wash the cells with 200 μl 1X PBS 3 times by centrifuge for 7 minutes, at 300 g, room 
temperature. Dilute 5 μl of 1 mg ml-1 PI solution in 5 ml of 1X PBS. Re-suspend the cells in 200 
μl of the PBS containing the 1 μg ml-1 PI. Store the cells at 4 oC prior to FACS analysis. 
PAUSE POINT The stained cells can be stored at 4 oC for up to 4 hours without losing much 
 22
viability.  
 
xii) Cells analysis by flow cytometry. Measure PE and PI fluorescence by channel 2 (yellow) and 
3 (red), respectively. Exclude PI positive cells (dead cells) in the data analysis. Determine the 
CXCR4 expression levels on CEM.NK cells after various treatments by the meaning 
fluorescence intensity of each cell sample. 
? TROUBLESHOOTING 
 
Option E. Doxorubicin Loading on Functionalized SWNTs 
i)  Mix 0.5 ml of PL-PEG5000-Amine functionalized SWNTs from Step 5 or RGD conjgauted 
SWNTs from Option A, step v with 30 μl 10 mM DOX solution. Add 50 μl 10xPBS and 2 μl 0.5 
M sodium bicarbonate buffer. The final pH is around 8. The final SWNT and DOX 
concentrations are ~40 mg/L and ~0.5 mM, respectively. Incubate the solution at 4 oC for 24 
hours. 
▲ CRITICAL STEP  Make sure the pH is not too basic. The SWNT-RGD-DOX will have 
reduced stability if pH is over 9. 
 
ii)  Remove excess DOX by an Amicon centrifugal filter device (MWCO = 10kDa). Wash at 
least 6 times with 3-4 ml water each time until the filtrate solution appears to be almost colorless. 
Re-suspend SWNT-DOX in 0.5 ml of water. Centrifuge the SWNT-DOX solution for 10 min, at 
10,000 xg, 4 oC, to remove aggregates. 
? TROUBLESHOOTING 
 
iii)  Record UV-VIS-NIR absorption spectra of SWNT (SWNT-RGD) and SWNT-DOX 
(SWNT-RGD-DOX) conjugates.21 To determine DOX loading onto SWNTs normalize the 
spectra by the absorption at 808 nm. DOX has a molar extinction coefficient of 1.05 × 104 
M-1?cm-1. The final DOX loading should be 600-800 DOX molecules per SWNT. 
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■ PAUSE POINT  The SWNT-DOX conjugate can be stored at 4 oC for 3~5 days without 
obvious losing of activity. 
 
iv) To determine the cell toxicity of the DOX conjugated SWNTs plate U87MG and MCF-7 cells 
in two 96-well plates with ~10,000 cells in 100 μl medium per well. Culture the cells overnight 
at 37 °C, 5% CO2. 
v) Centrifuge the SWNT-DOX solutions prepared in Step (iii) for 10 min at 10,000 xg, 4 oC, to 
remove any aggregates. Add a series of concentrations (1 μM to 40 μM) of free DOX, 
SWNT-DOX and SWNT-RGD-DOX into different wells of cells. Untreated cells in other wells 
are used as the control. Add each sample to triplicate wells. Incubate the plates for 1-2 h at 37 oC, 
5% CO2.  
vi) Gently wash cells with 200 μl 1x PBS twice for 7 minutes at 300g, room temperature, to 
remove excess drug. Add 100 μl of fresh cell medium and incubate at 37 oC, 5% CO2 for 48 h. 
vii) Measure the cell viability in each well using a CellTiter-96 kit following the manufacturer’s 
instructions. Measure the absorbance of the cells at 490 nm and determine the relative cell 
viabilities.21 
 
TIMING 
Step 1-5, functionalization of SWNTs 1-2 d 
Step 6 Option A, Conjugation of SWNTs with RGD peptide 3 d 
Step 6 Option B, Conjugation of SWNTs with antibody (Herceptin) 2 d 
Step 6 Option C, Radiolabeling of SWNTs 5 d 
Step 6 Option D, siRNA conjugation on SWNTs 5-6 d 
Step 6 Option E, Doxorubicin loading on functionalized SWNTs 5-6 d 
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TROUBLESHOOTING advice is showin in Table 1 
 
Table 1 TROUBLESHOOTING Advice 
Step Problem Possible Reason Solution 
2 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
Option 
C, vii 
 
 
 
Option 
D, ix 
 
 
 
 
 
 
 
 
 
SWNTs are not well 
suspended by PL-PEG. 
 
 
 
Nanotubes are very sticky on 
the filter device during 
filtration.. 
 
 
 
 
 
 
 
 
 
The radiolabeling yield is 
very low (e.g. <30%). 
 
 
 
Cells are contaminated by 
bacteria after 3 days 
incubation. 
 
 
 
 
 
 
 
 
Sonication is not efficient due to 
inappropriate vial position in the 
sonicator.  
 
 
A certain  amount of stickiness is 
normal for PL-PEG2000- Amine 
functionalization but not for 
PL-PEG5000- Amine This maybe 
due to poor coating of PL-PEG 
molecules on nanotubes. 
1) The PL-PEG/SWNT ratio is not 
enough when making nanotube 
suspensions. 
2) Water bath is too hot during 
sonication. 
 
This maybe due to metal ion 
contamination in the SWNT 
solution.  
 
 
SWNT solution is not well 
sterilized before adding into the cell 
culture.  
 
 
 
 
 
 
 
 
Adjust the position and angle of the 
vial in the sonicator. Make sure the 
water bath is at the recommended 
level. 
 
 
 
 
 
 
 
1) Reduce the amount of SWNTs or 
increase PL-PEG concentration 
during sonication. 
2) Change water in bath sonicator 
more frequently during sonication. 
 
Dialyze the SWNT solution against 
deionized distilled water with a 
10kDa MWCO membrane for 2 d 
before radiolabeling. 
 
Normally centrifuging SWNT- 
siRNA solution for 10 minat 10,000 
g  will resolve this problem. 
Repeating the centrifuge step 2-3 
times will be helpful. Carefully take 
out supernatant and discard any 
aggregates after centrifugation. Use 
sterilized containers during 
experiments. 
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Option 
E, ii 
 
A large amount of SWNT- 
DOX complex precipitates 
during centrifugation. 
 
 
The DOX loading on nanotubes is 
too high in this case. This stability 
issue is more frequent when making 
SWNT-RGD-DOX. 
 
1) Reduce pH in the loading 
solution to 7.8-8.0 by adding less 
sodium bicarbonate buffer. 
2) Add 10~20 μM PL-PEG into the 
loading solution. This will increase 
the stability of SWNT-RGD-DOX 
and not affect DOX loading and 
RGD targeting. 
 
 
ANTICIPATED RESULTS 
Functionalization of SWNTs  
After Step 5, PL-PEG functionalized SWNTs should have excellent water solubility and are 
stable in various biological solutions without any visible aggregation after a long period of 
incubation time (weeks) (Fig 5). Atomic force microscope (AFM) images of SWNTs show that 
the lengths of SWNTs range from 50 nm to 300 nm, with an average of ~100 nm. 
 
Targeting SWNT bioconjugates for Raman imaging and sensing  
 In Option A, step vii, confocal Raman spectroscopic images of cells stained by 
SWNT-RGD should exhibit strong SWNT Raman signals on integrin αvβ3 positive U87MG cells 
but not on negative MCF-7 cells (Fig. 6a). Non-specific binding of SWNTs to MCF-7 cells 
should be minimal. The ratio of Raman signals on positive verus negative cells is higher than 40 
(Fig. 6b). Raman imaging of BT474 (Her2 positive) and MCF-7 (Her2 negative) cells after 
staining with SWNT-Herceptin (Option B) should give very similar results (data not shown). 
Those targeted SWNT bioconjugates may also be used in ultra-sensitive protein microarray 
detection.14 
 
Radiolabeled SWNTs for in vivo PET imaging and tumor targeting  
 In Option C, step viii, PET images (Fig. 7) at 6 hours post injection should show high 
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tumor uptake (10-15%ID/g) in U87MG tumor bearing mice injected with SWNT-RGD 
(functionalized by PL-PEG5000).25 Radiolabeled SWNTs without RGD conjugation should 
show a reduced uptake in the tumor (3-5%ID/g) in comparison with RGD conjugated SWNTs.. 
Tumor uptake will be significantly reduced if mice are pre-injected with a high dose of free RGD 
peptide before injection of SWNT-RGD (4-6%ID/g). Control integrin αvβ3 negative HT29 
tumors should have a lower uptake of SWNT-RGD (3-5%ID/g) (Fig. 7d). 
 
SWNT based siRNA transfection and RNAi effect  
In Option D, step vii, as shown in Fig. 8, SWNT only and SWNT-siRNAluc mis-matched 
control treated CEM.NKR cells show normal CXCR4 expressions.4 CXCR4 expression should be 
significantly reduced after treatment with SWNT-siRNACXCR4 (two sequences) compared to 
untreated cells. The RNAi effect should range from 70-90%. Other types of commercial cationic 
liposome based siRNA transfection agents do not show significant siRNA transfection effects to 
CEM.NKR cells because human T cells are well known hard-to-transfect cells. 
 
Doxorubicin loading on functionalized SWNTs  
 In Option E, the SWNT-DOX solution should show a reddish color due to the UV-VIS 
absorption of DOX stacked onto SWNTs (Fig. 9a). The DOX absorption peak at 490 nm after 
subtraction of SWNT absorption at this wavelength is used to determine DOX concentration (Fig. 
9b). In Option E, step iv, SWNT-DOX has a lower toxicity than free DOX. Conjugation of 
RGD enhances the toxicity of DOX loaded SWNTs to integrin αvβ3 positive U87MG cells but 
not to negative MCF-7 cells (Fig. 9 c&d).21 
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Figure 1. Overview of the protocol. The protocol presented here contains five sub-protocols. 
Step 1-5 is the functionalization of SWNTs. Options A and B are conjugation of targeting ligands 
to SWNTs. Option C is radiolabeling of SWNTs. Option D is siRNA conjugation to SWNTs. 
Option E is doxorubicin loading onto functionalized SWNTs. 
 31
 
 
Figure 2. A scheme showing conjugation of targeting ligands to SWNTs. PL-PEG5000-Amine 
functionalized SWNTs are first activated by Sulfo-SMCC, yielding maleimide groups on SWNTs 
available for conjugation to thiolated antibodies or peptides. Thiolation of antibodies is carried 
out by treating them with Traut’s reagent. Thiolated RGD peptide is synthesized following a 
previous protocol and used directly.32 
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Figure 3. A scheme showing radiolabeling of targeting SWNTs bioconjugates. 
PL-PEG5000-Amine functionalized SWNTs are reacted with a mixture of Sulfo-SMCC and 
Sulfo-NHS activated DOTA. Thiolated peptides or antibodies are then conjugated to maleimide 
groups on SWNTs. The targeting SWNT bioconjugate is then labeled by radio isotopes such as 
64Cu through DOTA capture of metal ions. 
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Figure 4. A scheme showing siRNA conjugation to SWNTs via a disulfide bond. 
PL-PEG2000-Amine functionalized SWNTs are activated by the Sulfo-LC-SPDP bifuncitonal 
linker. The pyridyl disulfide group can then be coupled to thiolated siRNA to create a disulfide 
linkage via a thiol exchange reaction. 
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Figure 5. Functionalization of SWNTs by PL-PEG. (a) A photo showing PL-PEG2000-Amine 
functionalized SWNTs in PBS and RPMI-1640 cell medium (10% vol/vol FBS). The 
non-covalently functionalized SWNTs exhibit excellent stability in various biological solutions 
even after removal of excess PL-PEG molecules from the solution. (b) An Atomic Force 
Microscopy image of SWNTs on a silicon substrate. These SWNTs are mostly single nanotubes 
with a few small bundles, showing lengths of 50-300 nm. This figure is adapted from our 
previously published work with copyright obtained from Wiley InterScience. 4 
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Figure 6. Targeting SWNT bioconjugates for cell labeling and Raman imaging. Confocal Raman 
images of U87MG (integrin αvβ3 positive) and MCF-7 (integrin αvβ3 negative) cells (Left column) 
after incubation with SWNT-RGD for 1 hour at 4 °C (a). Optical images overlaid with Raman 
images are shown in the right column. Scale bar = 20 μm. (b) Averaged spectra of two Raman 
images in (a). Very strong Raman G-band signals are observed on U87MG cells. Negative 
MCF-7 cells exhibit minimal non-specific absorption signals of SWNT-RGD. This figure is 
adapted from previously published work14 
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Figure 7. Radiolabeled SWNTs for in vivo PET imaging and tumor targeting. Images are 
obtained at 6 hours post injection of radiolabeld nanotubes. (a) Control SWNTs without RGD 
conjugation show low uptake in the tumor. (b) High tumor SWNT uptake is observed for mice 
injected with SWNT-RGD. (c) A control experiment showing blocking of SWNT-RGD tumor 
uptake by co-injection of free c(RGDyK). (d) A control experiment showing low uptake of 
SWNT-RGD in integrin αvβ3-negative a tumor formed from HT-29 cells. Efficient tumor 
targeting is achieved by conjugating SWNTs with RGD peptide, which binds specifically to 
integrin αvβ3 expressed on tumor cells and tumor vasculature. The arrow points to the tumor on 
the mouse. Animal experiments were conducted under the protocols of Administrative Panel on 
Laboratory Animal Care (APLAC) at Stanford University. This figure is adapted from our 
previously published work25  
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Figure 8. CXCR4 expression levels on CEM.NK cells after various treatments indicated, 
including SWNT-siRNACXCR4a, SWNT-siRNACXCR4b, four types of commercial cationic 
liposome agents (Lipo1-4) and luciferase (Luc) siRNA control (SWNT-siRNAluc). The siRNA 
concentration is 500 nM in the incubation solution. Cells are incubated for 3 days prior to the 
FACS analysis. The expression levels of CXCR4 are determined using FACS analysis. Human T 
cells are not transfected by liposome based transfection agents. In contrast, SWNT based siRNA 
transfection method appears to be highly efficient to those cells. The error bars are based on 
standard deviation (SD) of triplicated samples. siRNACXCR4a and siRNACXCR4b both target 
CXCR4 mRNA but at different locations (different sequence). This figure is adapted from our 
previously published work with copyright obtained from Wiley InterScience. 4 
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Figure 9. Doxorubicin on functionalized SWNTs for drug delivery. (a) Photos of PL-PEG 
functionalized SWNT solutions with and without bound doxorubicin. (b) UV-VIS-NIR 
absorbance spectra of solutions of free doxorubicin (light blue), SWNTs with PL-PEG 
functionalization (black), and PL-PEG SWNTs complexed with doxorubicin (red) after simple 
incubation in a doxorubicin solution at pH 8-9. The absorption peak at 490nm is due to 
doxorubicin π-stacked on SWNTs, and used for analyzing the amount of molecule loaded onto 
nanotubes. (c&d) Concentration dependent survival curves of U87MG cells (c) and MCF-7 cells 
(d) treated with the various samples indicated. The viable cell percentages are measured by the 
MTS assay (CellTiter 96 kit). SWNT-DOX has relatively lower toxic effect than free DOX to 
both types of cells while SWNT-RGD-DOX exhibits increased toxicity to U87MG cells but not 
to MCF-7 cells. The viable percentage is normalized to the untreated control sample, which is 
determined as 100%. Error bars are based on standard deviations of triplicated samples. This 
figure is adapted from our previously published work with copyright obtained from ACS 
Publications.21  
 
